Trial Profile
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs Selgantolimod (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 11 Mar 2021 Results published in the Hepatology
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 11 Oct 2018 According to a Gilead Sciences media release, data from this trial will be presented at The Liver Meeting 2018 (Nov 2018).